Baloxavir marboxil
- Generic Name
- Baloxavir marboxil
- Brand Names
- Xofluza
- Drug Type
- Small Molecule
- Chemical Formula
- C27H23F2N3O7S
- CAS Number
- 1985606-14-1
- Unique Ingredient Identifier
- 505CXM6OHG
- Background
Baloxavir marboxil is an antiviral drug used to treat influenza. More specifically, it is a first-in-class cap-dependent endonuclease inhibitor that works to block influenza virus proliferation. It is a prodrug of baloxavir with an improved absorption profile than its active metabolite due to the addition of a phenolic hydroxyl group to its structure. Balox...
- Indication
Baloxavir marboxil is an influenza virus polymerase acidic (PA) endonuclease inhibitor indicated for the treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours and who are otherwise healthy adults and pediatric patients five years of age and older, or patients 12 years of age and older who are at high risk ...
- Associated Conditions
- Flu caused by Influenza, Acute, uncomplicated Influenza
- Associated Therapies
- -
Efficacy of Baloxavir Against Influenza in Hospitalized Patients: the INFLUENT Study (INpatients InFLUENza Treatment)
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Dre Pauline Vetter
- Target Recruit Count
- 484
- Registration Number
- NCT06653569
- Locations
- 🇨🇭
Geneva University Hospitals, Geneva, Switzerland
Evaluation of a Screen and Treat Protocol for Influenza
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Tricore, Inc
- Target Recruit Count
- 600
- Registration Number
- NCT06207058
Xofluza-Wearables Feasibility-Study
- Conditions
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Children's Hospital of Philadelphia
- Target Recruit Count
- 540
- Registration Number
- NCT06161454
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Participants With Influenza
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 600
- Registration Number
- NCT06094010
- Locations
- 🇺🇸
Velocity Clinical Research at Primary Pediatrics Macon, Macon, Georgia, United States
🇺🇸Kentucky Pediatric Research Center, Bardstown, Kentucky, United States
🇺🇸Velocity Clinical Research, Salt Lake City, West Jordan, Utah, United States
Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza
- Conditions
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 2
- Registration Number
- NCT05170009
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
- Conditions
- Interventions
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04712539
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Randomised Evaluation of COVID-19 Therapy
- Conditions
- Interventions
- Drug: Lopinavir-RitonavirBiological: Convalescent plasmaBiological: ImmunoglobulinDrug: CorticosteroidDrug: Synthetic neutralising antibodiesDrug: EmpagliflozinDrug: AnakinraDrug: High Dose CorticosteroidDrug: SotrovimabDrug: PaxlovidDrug: Baloxavir MarboxilDrug: HydroxychloroquineDrug: AzithromycinDrug: TocilizumabDrug: AspirinDrug: Dimethyl fumarateDrug: ColchicineDrug: BaricitinibDrug: OseltamivirDrug: Molnupiravir
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 70000
- Registration Number
- NCT04381936
- Locations
- 🇻🇳
Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam
🇬🇭Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Ghana
🇮🇳Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, New Delhi, India
Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle
- First Posted Date
- 2019-10-28
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 481
- Registration Number
- NCT04141930
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4176
- Registration Number
- NCT03969212
- Locations
- 🇯🇵
Uehara Clinic, Sapporo, Japan
🇺🇸Helios Clinical Research, Inc (former Ventavia Research Group), Kissimmee, Florida, United States
🇺🇸Mercury Clinical Research, Houston, Texas, United States
Study to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT03959332
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.